GNFTF - Inventiva resumes Phase 3 study for NASH drug stock up 6%
2024-03-08 13:46:51 ET
More on Inventiva
- Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause
- Inventiva drops after adverse event in Phase 3 trial for NASH drug
- Seeking Alpha’s Quant Rating on Inventiva
- Historical earnings data for Inventiva
- Financial information for Inventiva